T: 212.931.0704 | E: atamoshunas@tcllaw.com
Archana Tamoshunas focuses her practice on complex class action litigation, including antitrust and consumer protection litigation. Over her career, Ms. Tamoshunas has been counsel in numerous complex federal antitrust class actions and specializes in those involving the pharmaceutical and medical device industries. She is active in all aspects of the litigation process including day-to-day management of discovery, briefing, class certification and trial preparation.
Ms. Tamoshunas is Co-Lead Counsel in In re Copaxone Antitrust Litigation (D.N.J.) representing third party payors of Copaxone in an antitrust class action. She was appointed to the Advertising Class Steering Committee representing a proposed class of digital advertisers against Google in In re Google Digital Advertising Antitrust Litigation (S.D.N.Y.). and is a member of the Plaintiffs’ Steering Committee representing farmers in In re Crop Inputs Antitrust Litigation (E.D. Mo.). She also currently represents third party payors and purchasers of prescription drugs in other federal antitrust class actions alleging that pharmaceutical manufacturers have wrongfully prevented or delayed less expensive generic drugs from entering the market including, Government Employees Health Association v. Actelion Pharmaceuticals Ltd. (D. Md.) and In re Niaspan Antitrust Litigation (E.D. Pa.).
Ms. Tamoshunas has also represented direct purchasers in antitrust cases that have been successfully resolved including In re Lidoderm Antitrust Litigation (N.D. Cal.), in which her firm was appointed to the Executive Committee and she was personally involved in management and trial preparation of the case ($166 million settlement); In re Zetia (Ezetimibe) Antitrust Litigation (E.D.Va.) (Executive Committee); In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation (E.D. Pa.); In re Solodyn Antitrust Litigation (D. Mass.) ($72.5 million settlement); In re Skelaxin (Metaxalone) Antitrust Litigation (E.D. Tenn.) ($73 million settlement), In re Prandin Direct Purchaser Antitrust Litigation (E.D. Mich.) (Executive Committee) ($19 million settlement) and Mylan Pharmaceuticals v. Warner Chilcott (E.D. Pa.) ($15 million settlement), and was heavily involved in the management of successfully resolved cases including In re Relafen Antitrust Litigation (D. Mass.); In re Terazosin Hydrochloride Antitrust Litigation (S.D. Fla.) and Natchitoches Parish Hospital District et al. v. Tyco International, et al. (D. Mass.).
In 2021-2024, Ms. Tamoshunas was recognized as a New York Metro “Super Lawyer” in class action litigation. “Super Lawyer” selection results from peer nominations, a “blue ribbon” panel review process and independent research on candidates; no more than 5% of lawyers in the New York metro areas are selected as “Super Lawyers.”
Ms. Tamoshunas graduated from Williams College (B.A.) and from New York University School of Law, where she was a member of the Moot Court Board and had her case problem published in the New York University School of Law Moot Court Casebook (Vol. 22, 1998). After graduating from law school, Ms. Tamoshunas represented the City of New York in child abuse and neglect cases in Family Court.
Ms. Tamoshunas is admitted to the Bar of the State of New York as well as the Southern and Eastern Districts of New York, the Eastern District of Michigan and the First, Third and Eleventh Circuit Courts of Appeals. She is a member of the Antitrust Law Section of the New York State Bar Association.